{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 53,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "other",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Clinical trial summary slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/22",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "list",
      "text": "Clinicaltrials.gov: NCT05282797",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02f3b991-8422-4fe7-9e07-4c5381b6eca8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.58
      },
      "kind": "list",
      "text": "Part A: Proof of concept – completed, positive topline data released",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ebb3ac6-3b67-457b-b3ad-b813e09e7980",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "list",
      "text": "Primary Objective: To investigate the ability of ANEB-001 to inhibit the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "942e00e9-6429-47ab-86bf-fb3a82b1d351",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.66
      },
      "kind": "list",
      "text": "Part B: Extension of dose selection – ongoing (first 2 cohorts completed and third initiated)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2064af7-f6a5-4cff-98dd-f7589c3c953f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Study Design: Randomized, double-blind, placebo-controlled study in two parts. Healthy subjects challenged with an oral dose of THC and treated with ANEB-001.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be9a966d-6b95-475a-a728-89f45e1e00a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.04,
        "y": 0.74
      },
      "kind": "list",
      "text": "Study Site: Center for Human Drug Research (CHDR), Leiden, Netherlands",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfdfde33-b9c5-4cb7-b78d-81e9f6324119",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "list",
      "text": "Study Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of CB1 antagonist ANEB-001 in healthy occasional cannabis users",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0e1f764-1410-4f2a-9e5e-33864571792e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "ANEB-001 Phase 2 Proof of Concept Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8460814-6d06-4de8-8660-13b80174b5aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 20,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "1f2417df-59a7-4dba-a852-ef433df43395",
      "evidence": "The loop is opened by providing an update on ANEB-001's clinical development (slide 20) and closed by presenting positive results from the clinical trial (slides 24).",
      "position": 1,
      "objective": "How does ANEB-001 perform in clinical trials?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}